Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
FY June 2024-25 looks good with £0.6mln already booked in before it even starts and also due to hear from
Biostatistics service line
The Company was excited to announce its intention to develop a separate consulting service line focused on the delivery of biostatistics projects. Several complementary options are being pursued simultaneously to build out this new capability and a further update will be provided to the market towards the end of the current financial year. We anticipate that, if successful, this new service line could make a material contribution to the Company's revenues and bottom line in the financial year ending 30 June 2025.
Morning Laura, Interesting posts of late and thanks. Lets see if conference attendance results in contracts. Lucky to get your £700.00 order yesterday by the look of things there's no stock available today, well at present anyway!
Morning Ant
Yes,yesterday I put an order in and today I cannot buy at all
Morning All,
This is my first post on the PYC
I first bought some shares two weeks ago and have managed to make a small top up today at 11.23 for 25,000 shares.
I found it impossible to make a normal buy with HL but managed to succeed with a fill and kill order at 1.39.
I'm looking forward to an interesting and profitable investment in PYC.
Carliol
Morning All,
Looks like my modest top up has been the precursor to the 300,00 sell a few minutes later.
It's said in life there are only two certainties in life. Death and taxes. Now I'll add a third. Never follow my on the stock market.
I've traded shares for longer than I care to remember. I've always found it interesting but never boring.
Carliol
Car
Afternoon Carliol
At the current £1 7mln market capitalisation PYC is a very good buy
Hello Laura,
Patience is the key. The market cap is seriously under valuing PYC.
There are lots of prospective deals in the pipeline and I'm sure the San Diago conference will generate some new contacts and some new sales.
Carliol
Morning Carliol
They also completed 2 very large conference in April too ,would expect more business to come form there too
From March 2024
A significant number of new client contracts are now originating from both scientific conferences (such as EORTC-NCI-AACR & AACR Annual Meeting) as well as more business focused meetings (such as BioEurope
I agree with you but you must remember that some of us have been invested for over 20 years. The FDA's requirements for insilico prediction are very welcome but the company does need to pursue its objectives and advantage itself of their Act ( Dec 22 ). and not let the grass grow under its feet. We have all acknowledged that personalised medicine is the way forward and that the company is in a position at long last to realise its potential . Time is actually of the essence in this respect PYC needs to ensure that its sales techniques are in line with current thought, the time to sit back and relax are long gone. Critically if the board cannot sell their technology they need someone that can! I am so supportive but need to see action not talk or intellectual debate. I am buying and will continue to do so but shareholders need action to ensure their faith is justified! ! There are a lot of M&A opportunities out there and similarly royalty shares for service PYC need to be flexible and innovative!!
Ant, it would be great if you could try again to have dialogue with PYC. I have no doubt that Peter Sargent would be very receptive to any comments and suggestions you have for progressing the business
Emailed Dr Peter a few weeks ago - zero response
Trench with respect now is not the time . They have responses and feed back from 2 conferences that no doubt they will be addressing and are working on signing off two contracts that will form a major element / backbone of next years trading. There after we should receive more information on their pipeline. I know its a far better feeling to see the share price moving up but as others have said a little patience is required at moment and I totally agree. My average is approximately 1.38 and I am happy to continue buying sub 2p on information currently to hand. Once they publish news of progress I will re-evaluate this. As I have said previously the opportunities are out there and PYC is well placed to address them.
Can’t do any work without any staff????